Dana-Farber Cancer Institute- Site Number : 8400003

Boston, Massachusetts 02215

0 studies enrolling now · 2 studies all time

What they study most

Metastatic Neoplasm, Plasma Cell Myeloma

Studies at this site

• First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma — Completed
• A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Stopped early